How Has the Diphtheria Market Size Evolved in Recent Years?
The diphtheria market has seen considerable growth due to a variety of factors.
• In the last few years, the diphtheria market has seen robust growth. Its size is projected to increase from $8.91 billion in 2024 to $9.51 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.7%.
This growth in the historical timeframe can be credited to factors such as the development of vaccines, immunization drives, the rise in awareness, and improvements in healthcare infrastructure.
What Are The Predictions for The Diphtheria Market in the Coming Years?
The diphtheria market is expected to maintain its strong growth trajectory in upcoming years.
• Forecasted to witness a significant rise in the upcoming years, the diphtheria market is projected to magnify to $12.35 billion in 2029, surged by a compound annual growth rate (CAGR) of 6.8% . This anticipated growth during the forecast duration can be traced back to factors such as emerging outbreaks, reinforcement of vaccination programs, international travel and migration, and readiness of public health. Key market trends within the forecast period incorporate combination vaccines, the application of telemedicine for vaccination, initiatives for vaccine equity, and collaborations between public and private sectors.
Which Drivers Are Accelerating Growth In The Diphtheria Market?
The diphtheria market is predicted to expand due to the increasing cases of bacterial infections. Bacterial infections, diseases that arise from bacterial growth or toxins produced by invasive bacteria, are prevalent. Diphtheria, a critical bacterial infection, impairs the immune system while accelerating the growth of the Corynebacterium diphtheria bacterium. For instance, NHS acute trusts in England, as reported by GOV.UK, a government website of UK in September 2024, indicated that between the fiscal years 2022 and 2023, a total of 38,757 E. coli bacteremia cases were recorded, from which 7,881 cases (20.3%) were identified as hospital-onset infections. This increasing occurrence of bacterial infections is set to fuel the diphtheria market growth. The escalating immunization programs will further boost the diphtheria market growth. These programs, designed to offer vaccinations to people for prevention against vaccine-based diseases, aim to minimize disease-related sickness, impairment, and mortality rates. Various countries and regions, under these programs, administer diphtheria and other vaccines. As per the United Nations International Children's Emergency Fund, an institution responsible for children's developmental and humanitarian aid worldwide, the global coverage for the third dose of the Diphtheria, Tetanus, Pertussis (DTP3) vaccination rose to 84% in 2022 from 81% in 2021 via immunization. This upward trend in immunization programs is accelerating growth of the diphtheria market.
What Are The Core Segments Of The Global Diphtheria Market?
The diphtheria market covered in this report is segmented –
1) By Type: Diphtheria, Skin Diphtheria, Other Types
2) By Diagnosis: Physical Examination, Throat Culture, Other Diagnosis
3) By Treatment: Antibiotics, Antitoxin, Other Treatments
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Diphtheria: Respiratory Diphtheria, Non-respiratory Diphtheria
2) By Skin Diphtheria: Cutaneous Diphtheria
3) By Other Types: Diphtheritic Myocarditis, Diphtheritic Neuritis
Pre-Book The Diphtheria Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Diphtheria Market?
Significant entities in the diphtheria market are engineering novel medications and securing authorizations to maintain their industry dominance. For instance, in October 2022, GlaxoSmithKline PLC, a pharmaceutical and biotechnology firm based in the UK, disclosed that the US Food and Drug Administration (FDA) endorsed BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, adsorbed; Tdap) for immunization starting from the third month of pregnancy, aimed at thwarting pertussis (whooping cough) in infants less than two months old. Administering the Tdap vaccination during pregnancy provides the greatest protection against whooping cough during the initial months of a newborn's life. It is through immunization during pregnancy that protective antibodies are passed from the mother to her child.
Who Are the Key Players In The Diphtheria Market?
Major companies operating in the diphtheria market are:
• Pfizer Inc.
• Johnson & Johnson Co
• Roche Holding AG
• Merck & Co Inc.
• AbbVie Inc.
• Novartis AG
• Sanofi SA
• Bristol-Myers Squibb Co.
• AstraZeneca PLC
• GlaxoSmithKline PLC
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Moderna Inc.
• BioNTech SE
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• Vertex Pharmaceuticals Inc.
• Serum Institute of India
• Novavax Inc.
• Sinovac Biotech Ltd.
• Emergent BioSolutions Inc.
• Dynavax Technologies Corporation
• Bharat Biotech International Limited
• CureVac AG
• Inovio Pharmaceuticals Inc.
• The Native Antigen Company.
What Are The Regional Insights Into The Diphtheria Market?
Asia-Pacific was the largest region in the diphtheria market in 2024. The regions covered in diphtheria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
